TNF inhibitor

Strike First: TNFi vs. Step-Up Therapy in Early Peripheral SpA The approach to treating peripheral SpA has remained the same for a long time. The guidelines recommend starting with NSAIDs, escalating to conventional synthetic DMARDs, typically sulfasalazine or methotrexate, and https://t.co/iEqzp6FStv
Dr. John Cush @RheumNow( View Tweet )
Strike First: TNFi vs. Step-Up Therapy in Early Peripheral SpA The approach to the treatment of peripheral SpA has been the same for a long time. The guidelines recommend starting with NSAIDs, escalate to conventional synthetic DMARDs, typically sulfasalazine or methotrexate and https://t.co/pG9dGSfgcP
Dr. John Cush @RheumNow( View Tweet )
Who does better in active #RA b/tsDMARD naive? Pt choice TNFi or JAKi OR Pt randomized to TNFI or JAKi? Strangely or not PT choice did better ✅with satisfaction ~maybe expected ✅better retention on chosen #Rx 🤔unexpected another arm in #RCTS?” #EULAR2026 @RheumNow OP0204 https://t.co/7qx5Rqq6a7

Links:

Janet Pope @Janetbirdope( View Tweet )
A bridge to uncertainty? large #RCT of #baricitinib V #TNFi In Active #RA w #DVT/#VTE risk factor(s) Sl more VTE, #infection #SIE on #Bar NO increase #MACE Sl ⬆️#malignancy #VTE rate exceeded upper limit of a priori #CI So is this good news or not? #LB0009 @RheumNow #EULAR2026 https://t.co/CIfU7TL2TE

Links:

Janet Pope @Janetbirdope( View Tweet )
What’s new with the 2026 update of reco for vax in AIIRD? Vaccinate as soon as possible Non-live vaccines are safe Hold MTX for upto 2wks to inc vax yield Strong reco for RZV Catch-up vax for HPV in SLE Rotavirus vax for newborns exposed in utero to TNFi @RheumNow #EULAR2026 https://t.co/RZbyvAcYRI

Links:

sheila @RHEUMarampa( View Tweet )
Is the risk of uveitis comparable between infliximab sc and adalimumab in patients with r-axSpA and prior AAU? Yes! POS 1347 Multicenter randomised open-label trial N=56 #EULAR2026 @RheumNow https://t.co/kP7ropPkpC

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
#EULAR2026 LB0009 It’s like opening Pandora’s box! 2 Open Label RCTs Baricitinib vs TNF-i in RA & =>1 VTE risk: -VTE:Non-inferiority of BARI wasn’t met (in line with JAK profile) -No increase in MACE/Cancer (opposed to Oral-Surveillance: TOFA & =>1 MACE risk) @RheumNow #EULARBest https://t.co/nNwtJ3LbkD

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
LB0001: Bimekizumab SUPERIOR to risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.0078). First ever H2H biologic superiority on joints in PsA. #Bimekizumab @RheumNow #EULAR2026 https://t.co/6waepYs9RK

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
#EULAR2026 LB0002 More great news for dual IL17A and -F blockade. An open label Phase II study of Sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody'-3 in #axSpA: clinical efficacy, improvement in PROM and imaging inflammation. Looking forward to the RCT phase @RheumNow https://t.co/Xtxa8fALzN

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Abstr LB0009 Baricitinib vs TNFi in RA patients enriched for VTE risk. 3,640 patients. 3.7 years median follow-up. VTE: HR 1.61 (95% CI 0.97–2.66) non-inferiority not demonstrated MACE: HR 1.06 no cardiovascular excess Serious infections: HR 1.32 (p<0.05) @RheumNow https://t.co/NSNRJi9B4r

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Abstr LB0009 Baricitinib vs TNFi in VTE-enriched RA. 3,640 patients. 3.7 years. Safety endpoints VTE HR 1.61 non inferiority not met Serious infections HR 1.32 (p<0.05) MACE HR 1.06 reassuring @RheumNow #EULAR2026 https://t.co/nR6TMowlYS

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
BARI vs TNFi in VTE-enriched #RA pts (RA-BRIDGE + RA-BRANCH, n=3,640, ~3.7 yrs follow-up): VTE non-inferiority not met (HR 1.61, CI 0.97–2.66). But absolute rates low (2.5% vs 1.7%) and MACE was similar (HR 1.06). Serious infections ↑ with BARI. @RheumNow #EULAR2026 LB0009

Jiha Lee @JihaRheum( View Tweet )

#OP0209 #EULAR2026 SPECIFI-RA Balinatunfib, oral selective TNFR1 inhibitor designed to preserve TNFR2 signalling in RA. Phase 2b trial missed primary ACR20 endpoint, but 200mg QD arm showed signals for higher ACR50, ACR70 and DAS28 low disease activity & reduced IL-6. @RheumNow https://t.co/emxNQy0cPx

Links:

Mrinalini Dey @DrMiniDey( View Tweet )
Data of #Rituximab In #SARD-ILD Small N of #RA-#ILD pts I think data are sufficient as #RWE of #RTX in RA-ILD ✅benefits in other #CTD ILD ✅benefits in #rheumatoid #arthritis #EVER-ILD #RCT HOT #RA-ILD topic June 5 #EULAR2026 @RheumNow https://t.co/61MbsnNsaf

Links:

Janet Pope @Janetbirdope( View Tweet )
#OP0204 #EULAR2026 Shared decision-making in practice! BACH study tested “treat by choice” in RA. Patients preferred oral JAKi over SC TNFi (55% vs 45%) Importantly, own choice led to higher treatment satisfaction, better drug survival & fewer adverse events. @RheumNow #EULARBest https://t.co/iI1n2OGzqY

Links:

Mrinalini Dey @DrMiniDey( View Tweet )
EULAR meeting room

Strike First: TNFi vs. Step-Up Therapy in Early Peripheral SpA

Antoni Chan, MD, PhD

The approach to the treatment of peripheral SpA has been the same for a long time. The guidelines recommend starting with NSAIDs, escalate to conventional synthetic DMARDs, typically sulfasalazine or methotrexate and reserve biologics for patients who fail those. According to a new phase 3 trial

Read Article
Key messages in the tx of ax/p-SpA: >csDMARDs only effective in pSpA >consider individualized treatment for bDMARDs and JAKis >Cycling TNFi equally effective to switching @RheumNow #EULAR2026 https://t.co/oeO3BxmYYo

Links:

sheila @RHEUMarampa( View Tweet )
What b/ts DMARDs are effective and not effective in axSpA? Prof. Astrid van Tubergen presents this very informative summary slide summarizing treatment in axSpA. @RheumNow #EULAR2026 https://t.co/5udGPB1Hrr

Links:

sheila @RHEUMarampa( View Tweet )
Not just ticking boxes! Prof. Rudwaleit on the revised 2025 ASAS/SPARTAN criteria for axSpA What’s new? Providing a stem so criteria will be applied only if w/SpA dx, not just imaging MRI:active inflamm + structural lesions Some SpA features omitted @RheumNow #EULAR2026 https://t.co/NCV0EFvjYa

Links:

sheila @RHEUMarampa( View Tweet )
Gecacitinib (pan-JAK inhibitor) vs placebo in radiographic #axSpA ASAS40 51.9% vs 12.9% (p<0.0001) at 16 weeks. ASAS20 69.2% vs 21.2% (p<0.0001). Pan-JAK inhibition showed efficacy in TNFi-experienced patients. Abstr OP0240 @RheumNow #EULAR2026

Antoni Chan MD (Prof) @synovialjoints( View Tweet )

Does sequential therapy infliximab —> tofacitinib outperform tofa alone in axSpA? Yes: faster remission at week 4 (84.6% vs 15%) But: equal at week 24 Prospective study in 46 patients #POS0201 #EULAR2026 @RheumNow https://t.co/rmtoJQtYc0

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
10yr ffup data on 49pts from the OG CRESPA study (GOL vs PBO in very early pSpA): 81.6% (40/49) were in clinical remission 15 pts on drug-free remission 21 pts w/remission on meds still on GOL, no unSSAEs Early aggressive tx is key! AbsPOS0931 @RheumNow #EULAR2026 https://t.co/HrTF5XtAZt

Links:

sheila @RHEUMarampa( View Tweet )
psA.fil_.Hands_.jpg

What’s New in Psoriatic Arthritis: A Whirlwind Tour

Jiha Lee, MD

At the "What Is New in Psoriatic Arthritis" session at EULAR 2026, Professor Dennis McGonagle (Leeds, UK) took the audience on a whirlwind yet compact tour of the field, touching on three themes: the pathophysiology of PsA, individualization of clinical management, and emerging research and

Read Article
🧪 Can genetics predict TNFi response in PsA? OUTPASS GWAS (n=329): High BMI, comorbidities & novel XKR4 locus linked to non-response at 6 months #POS0087 #EULAR2026 @rheumnow

Nelly ZIADE 🍀 @Nellziade( View Tweet )

🎗️ Do targeted therapies raise cancer risk in SpA? French nationwide cohort (n=56,591): NO In fact, prolonged exposure REDUCES risk (wHR 0.86), especially haematological. #OP0238 #EULAR2026 @RheumNow https://t.co/dDveAmWpdX

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )

Recent Blogs

Advanced Practice Rheum

Safety of Biologics and Novel Agents

Jack Cush, MD
APR Safety Video Cover
Dr. Jack Cush reviews safety of biologics and novel agents.
Read Article
Advanced Practice Rheum

Systemic Lupus Erythematosus

Jack Cush, MD
APR SLE VIDEO COVER
Dr. Cush reviews systemic lupus erythematosus.
Read Article
Advanced Practice Rheum

Difficult to Treat Rheumatoid Arthritis

Jack Cush, MD
D2T RA Cover
Dr. Cush addresses the management of difficult-to-treat rheumatoid arthritis (D2TRA).
Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • ACR 2025 SpA Topic Podcasts Compilation 1
  • ACR 2025 Daily Podcasts Day2d
  • EULAR 2021 - Day2a 00:38:00
×